Militia Capital Management LLC Acquires New Position in TransMedics Group, Inc. $TMDX

Militia Capital Management LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 21,000 shares of the company’s stock, valued at approximately $2,088,000.

Other hedge funds have also added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the third quarter valued at approximately $29,000. Allworth Financial LP grew its stake in TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Parallel Advisors LLC grew its stake in TransMedics Group by 42.1% in the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares in the last quarter. Ascentis Independent Advisors purchased a new position in TransMedics Group during the 1st quarter worth $30,000. Finally, North Star Investment Management Corp. bought a new stake in TransMedics Group during the 1st quarter valued at $30,000. 99.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TMDX. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research note on Wednesday, July 22nd. Oppenheimer cut shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Stifel Nicolaus upped their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $129.55.

TransMedics Group Price Performance

Shares of TMDX stock opened at $76.51 on Monday. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The stock’s 50-day moving average is $72.55 and its 200 day moving average is $100.58. The company has a market cap of $2.64 billion, a P/E ratio of 17.39 and a beta of 1.89. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the prior year, the firm posted $0.70 earnings per share. The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post 1.88 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.